Key Dimensions of PTSD and ED
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Cardiology, Hospital, Psychiatric |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/20/2018 |
| Start Date: | January 2019 |
| End Date: | June 30, 2023 |
| Contact: | Jacob Julian, BA |
| Email: | jej2140@cumc.columbia.edu |
| Phone: | 347-573-3344 |
Key Dimensions of Post-traumatic Stress Disorder (PTSD) and Endothelial Dysfunction (ED)
This study will test whether endothelial dysfunction could be the early subclinical mechanism
by which posttraumatic stress disorder (PTSD) increases cardiovascular disease (CVD) risk,
and whether posttraumatic fear—a key component of PTSD—or another PTSD dimension could be the
target to offset that risk. The results of this study may help trauma-exposed individuals who
are at risk of having CVD events.
by which posttraumatic stress disorder (PTSD) increases cardiovascular disease (CVD) risk,
and whether posttraumatic fear—a key component of PTSD—or another PTSD dimension could be the
target to offset that risk. The results of this study may help trauma-exposed individuals who
are at risk of having CVD events.
Posttraumatic stress disorder (PTSD) increases risk of incident cardiovascular disease (CVD)
by 25-50%. Most individuals (50-90%) experience a traumatic event in their lifetime, and PTSD
is the fifth most common psychiatric disorder. Experts have now called for increased CVD
surveillance after trauma and for PTSD treatment trials powered to reduce CVD risk. However,
both CVD risk and PTSD are complex phenomena that likely interact in nuanced ways. This study
will determine which PTSD dimension(s) contribute to endothelial dysfunction, one of the
earliest modifiable precursors to CVD. The investigators will examine cross-sectional and
longitudinal associations of PTSD and its underlying dimensions with functional and,
secondarily, cellular measures of endothelial dysfunction (FMD and circulating endothelial
cell-derived microparticles, respectively) in a community-dwelling sample of CVD-free adult
men and women with a history of trauma (50% with current PTSD).
by 25-50%. Most individuals (50-90%) experience a traumatic event in their lifetime, and PTSD
is the fifth most common psychiatric disorder. Experts have now called for increased CVD
surveillance after trauma and for PTSD treatment trials powered to reduce CVD risk. However,
both CVD risk and PTSD are complex phenomena that likely interact in nuanced ways. This study
will determine which PTSD dimension(s) contribute to endothelial dysfunction, one of the
earliest modifiable precursors to CVD. The investigators will examine cross-sectional and
longitudinal associations of PTSD and its underlying dimensions with functional and,
secondarily, cellular measures of endothelial dysfunction (FMD and circulating endothelial
cell-derived microparticles, respectively) in a community-dwelling sample of CVD-free adult
men and women with a history of trauma (50% with current PTSD).
Inclusion Criteria:
- Aged 18+ years
- History of exposure to a psychological trauma (e.g., natural disaster, physical
assault)
- Fluent in English
- Willing to and capable of providing informed consent
Additional Inclusion Criteria for the PTSD Group
- Diagnosed with current PTSD (duration of at least 1 month) using the
Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual 5th Edition
(DSM-5) (CAPS-5) at the diagnostic interview assessment
Exclusion Criteria:
- History of CVD (i.e., diagnosis of myocardial infarction, unstable angina, heart
failure, peripheral artery disease, or stroke)
- Deemed unable to comply with the protocol (either self-selected or by indicating
during screening that could not complete all requested tasks)
- Current bipolar disorder or psychotic disorder
- Current dementia diagnosis
- Current moderate or severe substance use disorder
- Acute, unstable, or severe medical disorder
- Deemed to need immediate psychiatric intervention (e.g., active suicidality)
Additional Exclusion Criteria for the Trauma-Exposed Matched Control Group
- Current diagnosis of any DSM-5 psychiatric disorder
- CAPS-5 total score ≥25
We found this trial at
1
site
630 W 168th St
New York, New York
New York, New York
212-305-2862
Principal Investigator: Jennifer Sumner, PhD
Phone: 347-573-3344
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
